The April 1, 2016, article by Piccart-Gebhart et al entitled “Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial” (J Clin Oncol 34:1034-1042, 2016) was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Dr. Baselga’s COIs were given as:
José Baselga
Consulting or Advisory Role: Novartis, Juno Therapeutics, Aura Biosciences, Verastem, Infinity Pharmaceuticals
They should have read as:
José Baselga
Leadership: Infinity Pharmaceuticals, Aura Biosciences
Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biosciences, Apogen, Seragon
Honoraria: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Seragon
Consulting or Advisory Role: Novartis, Eli Lilly, GRAIL, AstraZeneca
Research Funding: Roche/Genentech
Travel, Accommodations, Expenses: Roche/Genentech
This has been corrected as of January 11, 2019. The author apologizes for the errors.